Appointments Expand Leading Biology, Chemistry and Clinical Drug Development Expertise
“We are thrilled to expand Kinagen’s team with leading chemistry, biology and clinical perspectives. This is an exceptional group to guide advancement of our RAF Blockade™ drug candidate into the clinic and apply the Kinagen Platform™ to generate differentiated drug candidates,” commented David Slack, President & CEO.
David Cheresh, Ph.D. co-founded Kinagen. He has been responsible for advances in angiogenesis and cancer research, and multiple drugs advancing in the clinic. He currently serves as Vice Chair for Research, Department of Pathology, and Professor, Department of Pathology, Moores UCSD Cancer Center.
Lee Arnold, Ph.D. made significant contributions to Kinagen programs and has a track record of advancing drugs into the clinic, including discovery and advancement of Tarceva® and several other kinase-targeted drugs. He previously served as VP Oncology Drug Discovery at OSI Pharmaceuticals and in senior medicinal chemistry roles at Pfizer and Abbott.
Homer Pearce, Ph.D. has extensive drug discovery and development experience. He previously led Oncology R&D at Eli Lilly, where he oversaw discovery, development and approval of cancer drugs including Gemzar® and Alimta®.
Peter Farina, Ph.D. has overseen innovative kinase-targeted drug discovery programs. He previously served as Senior VP of Development at Boehringer Ingelheim Pharmaceuticals and is currently an Executive-in-Residence at Canaan Partners.
Keith Flaherty, M.D. is a clinical oncologist, focused on biomarkers to define mechanisms and identify optimal target patient populations. He has been at the forefront of clinical research for innovative kinase-targeted cancer drug development. Keith currently serves as Director of Developmental Therapeutics for the Cancer Center at Massachusetts General Hospital and as a lecturer at Harvard Medical School.
Kinagen is an emerging drug discovery and development company, positioned to establish a new class of drugs that stabilize kinases in an inactive state. The drug discovery approach embodied in the Kinagen Platform™ provides efficacy and safety advantages that will result in improved treatments for patients. Kinagen’s RAF Blockade™ drug candidate addresses limitations of other approaches and promises to provide durable benefits to a broad range of cancer patients.
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical General Health